Patents by Inventor María Concepción Jimenez Gomez

María Concepción Jimenez Gomez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8354385
    Abstract: The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: January 15, 2013
    Assignee: Sylentis S.A.U.
    Inventors: Maria Del Carmen Acosta Boj, Juana Gallar Martinez, Angela Sesto Yague, Carlos Belmonte Martinez, Ana Isabel Jimenez Anton, Maria Concepcion Jimenez Gomez
  • Patent number: 8188057
    Abstract: The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1).
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: May 29, 2012
    Assignee: Sylentis S.A.U.
    Inventors: Ana Isabel Jiménez Anton, Ángela Seso Yague, María Concepción Jiménez Gomez
  • Publication number: 20110160277
    Abstract: The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1).
    Type: Application
    Filed: October 25, 2006
    Publication date: June 30, 2011
    Applicant: SYLENTIS S.A.U.
    Inventors: Ana Isabel Jiménez Anton, Ángela Sesto Yague, María Concepción Jimenez Gomez
  • Publication number: 20100286230
    Abstract: The present invention relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1 (TRPV1). Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes and diabetic retinopathy.
    Type: Application
    Filed: October 20, 2006
    Publication date: November 11, 2010
    Applicant: SYLENTIS S.A.U.
    Inventors: Maria del Carmen Acosta Boj, Juana Gallar Martinez, Angela Sesto Yague, Carlos Belmonte Martinez, Ana Isabel Jimenez Anton, Maria Concepcion Jimenez Gomez